RISA Labs is a technology company.
RISA Labs has raised $4.0M across 1 funding round.
RISA Labs has raised $4.0M in total across 1 funding round.
RISA Labs has raised $4.0M in total across 1 funding round.
RISA Labs's investors include Alpha Venture Partners, Santé Ventures.
RISA Labs is an early-stage healthcare technology company founded in 2024 that builds an AI-powered platform automating prior authorizations for oncology treatments.[1][2] Its core product, BOSS, serves hospitals and healthcare providers by slashing prior authorization time from 30 minutes to under five minutes through AI agents that handle medical necessity checks, form population, submission via APIs/portals/e-fax, and denial management.[1][2] The platform tackles administrative burdens in oncology workflows, reducing denial rates, compliance risks, and manual labor while integrating with 90+ EHRs like Epic and Cerner, positioning it for growth in the $80 billion global healthcare automation market after raising $3.5M in seed funding from Z47 and 3States.[1][3]
RISA Labs was founded in 2024 in Palo Alto, California, by Kshitij Jaggi and Kumar Shivang as a three-person "AI Research group" focused on multi-agent systems for healthcare operations.[1][4] The idea emerged from the healthcare community's need to reimagine oncology workflows, starting with prior authorizations—a notorious bottleneck involving payer rules, EHR data, and manual tasks.[2][4] Early traction came swiftly with a seed VC round of $3.5M just two months before mid-2025, validating their AI-driven approach amid rising demand for automation in high-risk care.[1]
RISA Labs rides the AI healthcare automation wave, targeting oncology's administrative inefficiencies amid payer scrutiny and rising treatment costs.[1][2] Timing aligns with post-2024 AI maturity in multi-agent systems and regulatory pushes for faster approvals, fueled by a $80B market opportunity as providers face burnout from 30-minute auths.[1] It influences the ecosystem by enabling unified AI orchestration across oncology nodes, integrating with incumbents like Availity, and reducing denials—potentially scaling to general healthcare ops and pressuring legacy players to adopt AI.[2][3]
RISA Labs is primed to expand BOSS beyond prior auth into full oncology orchestration, leveraging its seed momentum and integrations to capture market share in a denial-plagued sector.[1][2] Trends like AI agent proliferation, FHIR standardization, and value-based care will accelerate adoption, though competition from AKASA and scaling human-AI handoffs pose risks. Its influence could evolve from niche oncology disruptor to foundational layer in precision healthcare ops, amplifying provider efficiency and patient access in an AI-redefined industry.[1][5]
RISA Labs has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $4.0M Seed | Alpha Venture Partners, Santé Ventures |